 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 July 1996 | Volume 125 Issue 1 | Pages 19-25
Background: Previous research has shown that the insertion/deletion (I/D) polymorphism of the angiotensin I-converting enzyme (ACE) gene is a major determinant of plasma ACE activity. It has been suggested that persons with the DD genotype (those who express, on average, the highest levels of circulating ACE) have an increased risk for myocardial infarction and coronary artery disease, particularly if they are otherwise at low risk. Subsequent studies, however, have not confirmed that ACE I/D gene polymorphism is a risk factor for coronary artery disease and myocardial infarction.
Objective: To investigate the association between the I/D polymorphism of the ACE gene and the risk for coronary artery disease and myocardial infarction in patients in whom coronary artery disease status was documented by angiography.
Design: Cross-sectional study.
Setting: University medical center.
Patients: 209 male case-patients with coronary artery disease and 92 male controls without coronary artery disease, as documented by coronary angiography.
Measurements: Assessment of the cardiac risk profile by questionnaire; classification of patients by the degree of coronary artery stenosis; levels of lipoproteins, apolipoproteins, and fibrinogen; and ACE I/D gene polymorphism assessed by polymerase chain reaction amplification.
Results: Plasma ACE activity was significantly associated with ACE I/D gene polymorphism. The ACE genotype was not associated with the presence of coronary artery disease or myocardial infarction. If a recessive effect of the D allele was assumed (DD compared with DI and II), the relative risk was 1.00 (95% CI, 0.76 to 1.30) for coronary artery disease and 1.03 (CI, 0.77 to 1.38) for myocardial infarction. Results of analyses were also negative when a dominant effect of the D allele was assumed and when low-risk subgroups were examined. The established risk factors age and apolipoprotein B level emerged as the most important risk predictors in multivariate analyses, followed by diastolic blood pressure and fasting glucose levels.
Conclusions: In an angiographically defined study sample, ACE I/D gene polymorphism was not associated with an increased risk for coronary artery disease or myocardial infarction, despite its effects on plasma ACE activity.
Author and Article Information
From the Johann Wolfgang Goethe-University, Frankfurt, Germany.
ARTICLE
Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Is Associated with Increased Plasma Angiotensin-Converting Enzyme Activity but Not with Increased Risk for Myocardial Infarction and Coronary Artery Disease
Grant Support: By a research grant from Bristol-Myers Squibb GmbH, Munich, Germany, and a research grant from Forschungsschwerpunkt Land Baden-Wurttemberg.
Requests for Reprints: Bernhard R. Winkelmann, MD, Hoechst AG, Klinische Forschung H840, 65926 Frankfurt, Germany.
Current Author Addresses: Drs. Winkelmann and Verho: Hoechst AG, Klinische Forschung H840, 65926 Frankfurt, Germany.
This article has been cited by other articles:
|
|
 |
|
  E. Zintzaras, G. Raman, G. Kitsios, and J. Lau Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphic Variant as a Marker of Coronary Artery Disease: A Meta-analysis Arch Intern Med, May 26, 2008; 168(10): 1077 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McNamara, R. Holubkov, L. Postava, K. Janosko, G. A. MacGowan, M. Mathier, S. Murali, A. M. Feldman, and B. London Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure J. Am. Coll. Cardiol., November 16, 2004; 44(10): 2019 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Slowik, A. Borratynska, J. Pera, M. Betlej, T. Dziedzic, T. Krzyszkowski, R. Czepko, D. A. Figlewicz, and A. Szczudlik II Genotype of the Angiotensin-Converting Enzyme Gene Increases the Risk for Subarachnoid Hemorrhage From Ruptured Aneurysm Stroke, July 1, 2004; 35(7): 1594 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Chaves, D. Corella, J. V. Sorli, P. Marin-Garcia, M. Guillen, and J. Redon Polymorphisms of the Renin-Angiotensin System Influence Height in Normotensive Women in a Spanish Population J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2301 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Feldman The emerging role of pharmacogenomics in the treatment of patients with heart failure Ann. Thorac. Surg., December 1, 2003; 76(6): S2246 - 2253. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Ryan, B. J. Nicklas, D. M. Berman, and R. E. Ferrell The Insertion/Deletion Polymorphism of the ACE Gene Is Related to Insulin Sensitivity in Overweight Women Diabetes Care, September 1, 2001; 24(9): 1646 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J. J. Wang, G. A. MacGowan, S. Murali, W. D. Rosenblum, B. London, and A. M. Feldman Pharmacogenetic Interactions Between {beta}-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure Circulation, March 27, 2001; 103(12): 1644 - 1648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishimitsu, K. Hosoya, and H. Matsuoka The Deletion Allele of Angiotensin-Converting Enzyme Gene Polymorphism as a Cardiovascular Risk Factor in Patients Undergoing Long-Term Hemodialysis Ann Intern Med, December 5, 2000; 133(11): 924 - 924. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Agerholm-Larsen, B. G. Nordestgaard, and A. Tybjarg-Hansen ACE Gene Polymorphism in Cardiovascular Disease : Meta-Analyses of Small and Large Studies in Whites Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 484 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Anderson, E. Elstein, H. Haber, and F. Charbonneau Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) J. Am. Coll. Cardiol., January 1, 2000; 35(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Deedwania Endothelium: a new target for cardiovascular therapeutics J. Am. Coll. Cardiol., January 1, 2000; 35(1): 67 - 70. [Full Text] [PDF]
|
|
|
|
|
|
D. Henrion, J. Benessiano, I. Philip, S. Vuillaumier-Barrot, M. Iglarz, G. Plantefeve, D. Chatel, U. Hvass, G. Durand, J.-M. Desmonts, et al. The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro J. Am. Coll. Cardiol., September 1, 1999; 34(3): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Bogardus Jr, J. Concato, and A. R. Feinstein Clinical Epidemiological Quality in Molecular Genetic Research: The Need for Methodological Standards JAMA, May 26, 1999; 281(20): 1919 - 1926. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. R. M. Osterop, M. J. M. Kofflard, L. A. Sandkuijl, F. J. t. Cate, R. Krams, M. A. D. H. Schalekamp, and A. H. J. Danser AT1 Receptor A/C1166 Polymorphism Contributes to Cardiac Hypertrophy in Subjects With Hypertrophic Cardiomyopathy Hypertension, November 1, 1998; 32(5): 825 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. O'Donnell, K. Lindpaintner, M. G. Larson, V. S. Rao, J. M. Ordovas, E. J. Schaefer, R. H. Myers, and D. Levy Evidence for Association and Genetic Linkage of the Angiotensin-Converting Enzyme Locus With Hypertension and Blood Pressure in Men but Not Women in the Framingham Heart Study Circulation, May 19, 1998; 97(18): 1766 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. P. Mancini, M. Margaglione, A. Tufano, A. Celentano, L. A. Ferrara, V. Colantuoni, G. Di Minno, A. Tybjærg-Hansen, B. Agerholm-Larsen, and B. G. Nordestgaard A Fast and Accurate Method for Genotyping the Angiotensin-Converting Enzyme I/D Polymorphism • Response Circulation, March 31, 1998; 97(12): 1213 - 1214. [Full Text] [PDF]
|
|
|
|
|
|
B. Tian, Q. C. Meng, Y.-F. Chen, J. H. Krege, O. Smithies, and S. Oparil Blood Pressures and Cardiovascular Homeostasis in Mice Having Reduced or Absent Angiotensin-Converting Enzyme Gene Function Hypertension, July 1, 1997; 30(1): 128 - 133. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Krege, H.-S. Kim, J. S. Moyer, J. C. Jennette, L. Peng, S. K. Hiller, and O. Smithies Angiotensin-Converting Enzyme Gene Mutations, Blood Pressures, and Cardiovascular Homeostasis Hypertension, January 1, 1997; 29(1): 150 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ACE Gene Abnormality and CAD Risk Journal Watch Cardiology, October 1, 1996; 1996(1001): 12 - 12. [Full Text]
|
|
Article
